Free signup for more
- Track your favorite companies
- Receive email alerts for new filings
- Personalized dashboard of news and more
- Access all data and search results
Filing tables
Filing exhibits
- S-4/A Registration of securities issued in business combination transactions
- 5.1 Opinion of Ellenoff Grossman & Schole LLP
- 8.1 Tax Opinion of Ellenoff Grossman & Schole LLP
- 10.15 Offer Letter, Dated As of July 18, 2016, by and Between Blade Theraueptics, Inc. and Wendye Robbins, M.D
- 10.16 Offer Letter, Dated As of February 1, 2021, by and Between Blade Therapeutics, Inc. and Jean-frederic Viret, PH.D
- 10.17 Offer Letter, Dated As of April 19, 2017, by and Between Blade Therapeutics, Inc. and Prabha Ibrahim, PH.D
- 10.18 Offer Letter, Dated As of September 30, 2016, by and Between Blade Therapeutics, Inc. and Felix Karim, PH.D
- 10.19 Amendment to Offer Letter, Dated As of March 24, 2022, by and Between Blade Biotherapeutics, Inc. and Wendye Robbins, M.D
- 10.20 Amendment to Offer Letter, Dated As of March 24, 2022, by and Between Blade Biotherapeutics, Inc. and Jean-frederic Viret, PH.D
- 10.21 Amendment to Offer Letter, Dated As of March 24, 2022, by and Between Blade Biotherapeutics, Inc. and Prabha Ibrahim, PH.D
- 10.22 Amendment to Offer Letter, Dated As of March 24, 2022, by and Between Blade Biotherapeutics, Inc. and Felix Karim, PH.D
- 23.1 Consent of Marcum LLP
- 23.2 Consent of Ernst and Young LLP, Independent Registered Accounting Firm for Blade Therapeutics, Inc
- 99.2 Consent of Wendye Robbins to Be Named As a Director
- 99.3 Consent of Mark Timney to Be Named As a Director
- 99.4 Consent of Lloyd Klickstein to Be Named As a Director
- 99.5 Consent of James Scopa to Be Named As a Director
- 99.6 Consent of Luke Evnin to Be Named As a Director
- 99.7 Consent of John A. Hohneker, M.D. to Be Named As a Director
- 99.8 Consent of Carl Goldfischer, M.D. to Be Named As a Director
- Download Excel data file
- View Excel data file
Associated filings
- 17 Jun 22 RW Registration withdrawal request
- 23 May 22 424B3 Prospectus supplement
- 10 May 22 EFFECT Notice of effectiveness
- 9 May 22 424B3 Prospectus supplement
- 9 May 22 S-4/A Registration of securities issued in business combination transactions (amended)
- 3 May 22 S-4/A Registration of securities issued in business combination transactions (amended)
-
15 Apr 22 S-4/A Registration of securities issued in business combination transactions (amended)
- 1 Apr 22 S-4/A Registration of securities issued in business combination transactions (amended)
- 15 Mar 22 S-4 Registration of securities issued in business combination transactions
BIOT similar filings
Filing view
External links
Exhibit 23.2
Consent of Ernst & Young LLP, Independent Registered Public Accounting Firm
We consent to the reference to our firm under the caption “Experts” and to the use of our report dated March 15, 2022, with respect to the consolidated financial statements of Blade Therapeutics, Inc. included in the proxy statement/prospectus of Biotech Acquisition Company that is made a part of Amendment No. 2 to the Registration Statement (Form S-4 No. 333-263577) and Prospectus of Biotech Acquisition Company for the registration of its common stock.
/s/ Ernst & Young LLP
Redwood City, California
April 15, 2022